Merck EPS rise by 15% to $1.18 in Q2

Friday, 31. July 2020 12:51

American pharmaceutical giant Merck &Co. Inc. said on Friday that its earnings per share (EPS) jumped 15% in the second quarter, to reach $1.18.

Net income rose by 17% to $3 billion while the cost of sales stood at $3.1 billion.

"Despite the impact COVID-19 had on patient access to health care providers, Merck continued to execute well with business momentum improving through the quarter. We remain confident that Merck will drive strong long-term growth based on underlying demand for our unique portfolio of innovative medicines, vaccines and animal health products. Our financial strength underpins our capital allocation priorities, including business development and the breakthrough research and development that creates value for society and our shareholders," said CEO Kenneth C. Frazier.

Related Links: Merck KGaA
Author:
Breaking the News / TF